Do analysts recommend GCTK or ICCM?

IceCure Medical has a consensus target price of $52.50, indicating a potential upside of 2,060.49%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is GCTK or ICCM more profitable?

GlucoTrack has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% IceCure Medical -427.67% -174.26% -112.58%

Does the media prefer GCTK or ICCM?

In the previous week, GlucoTrack and GlucoTrack both had 3 articles in the media. GlucoTrack's average media sentiment score of 0.44 beat IceCure Medical's score of -0.14 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend HSCS or GCTK?

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 185.71%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, HSCS or GCTK?

HeartSciences is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$9.14M -$3.94 N/A GlucoTrack N/A N/A -$19.39M -$9.18 N/A

Is HSCS or GCTK more profitable?

HeartSciences' return on equity of -358.60% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -358.60% -144.82% GlucoTrack N/A -2,135.52% -290.22%

Does the media favor HSCS or GCTK?

In the previous week, HeartSciences had 1 more articles in the media than GlucoTrack. MarketBeat recorded 4 mentions for HeartSciences and 3 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.44 beat HeartSciences' score of 0.18 indicating that GlucoTrack is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GCTK or INBS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to GCTK or INBS?

In the previous week, GlucoTrack and GlucoTrack both had 3 articles in the media. Intelligent Bio Solutions' average media sentiment score of 0.89 beat GlucoTrack's score of 0.44 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intelligent Bio Solutions 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NVNO or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, NVNO or GCTK?

enVVeno Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$19.33 N/A GlucoTrack N/A N/A -$19.39M -$9.18 N/A

Is NVNO or GCTK more profitable?

enVVeno Medical's return on equity of -62.28% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -62.28% -56.83% GlucoTrack N/A -2,135.52% -290.22%

Do analysts prefer GCTK or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor GCTK or NXL?

In the previous week, GlucoTrack and GlucoTrack both had 3 articles in the media. GlucoTrack's average media sentiment score of 0.44 beat Nexalin Technology's score of 0.34 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nexalin Technology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GlucoTrack (GCTK) Competitors

$0.35 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

GCTK vs. ICCM, HSCS, INBS, NVNO, and NXL

Should you buy GlucoTrack stock or one of its competitors? GlucoTrack's main competitors and comparable companies include IceCure Medical (ICCM), HeartSciences (HSCS), Intelligent Bio Solutions (INBS), enVVeno Medical (NVNO), and Nexalin Technology (NXL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does GlucoTrack compare to IceCure Medical?

GlucoTrack (NASDAQ:GCTK) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

GlucoTrack has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
IceCure Medical	-427.67%	-174.26%	-112.58%

In the previous week, GlucoTrack and GlucoTrack both had 3 articles in the media. GlucoTrack's average media sentiment score of 0.44 beat IceCure Medical's score of -0.14 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

IceCure Medical has a consensus target price of $52.50, indicating a potential upside of 2,060.49%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 5.9% of GlucoTrack shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IceCure Medical has higher revenue and earnings than GlucoTrack. IceCure Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$9.18	N/A
IceCure Medical	$3.38M	2.47	-$15.06M	-$8.52	N/A

GlucoTrack has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Summary

IceCure Medical beats GlucoTrack on 8 of the 14 factors compared between the two stocks.

How does GlucoTrack compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

HeartSciences currently has a consensus price target of $8.00, indicating a potential upside of 185.71%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HeartSciences has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Comparatively, 5.9% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HeartSciences' return on equity of -358.60% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-358.60%	-144.82%
GlucoTrack	N/A	-2,135.52%	-290.22%

In the previous week, HeartSciences had 1 more articles in the media than GlucoTrack. MarketBeat recorded 4 mentions for HeartSciences and 3 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.44 beat HeartSciences' score of 0.18 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$9.18	N/A

Summary

HeartSciences beats GlucoTrack on 10 of the 13 factors compared between the two stocks.

How does GlucoTrack compare to Intelligent Bio Solutions?

GlucoTrack (NASDAQ:GCTK) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, GlucoTrack and GlucoTrack both had 3 articles in the media. Intelligent Bio Solutions' average media sentiment score of 0.89 beat GlucoTrack's score of 0.44 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intelligent Bio Solutions	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 5.9% of GlucoTrack shares are held by insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GlucoTrack has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Intelligent Bio Solutions' return on equity of -175.35% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%

Intelligent Bio Solutions has higher revenue and earnings than GlucoTrack. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$9.18	N/A
Intelligent Bio Solutions	$4.22M	1.80	-$12.43M	-$9.02	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

GlucoTrack has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.21, meaning that its stock price is 321% more volatile than the broader market.

Summary

Intelligent Bio Solutions beats GlucoTrack on 9 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

enVVeno Medical's return on equity of -62.28% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
GlucoTrack	N/A	-2,135.52%	-290.22%

enVVeno Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$9.18	N/A

enVVeno Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by insiders. Comparatively, 5.9% of GlucoTrack shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GlucoTrack had 3 more articles in the media than enVVeno Medical. MarketBeat recorded 3 mentions for GlucoTrack and 0 mentions for enVVeno Medical. GlucoTrack's average media sentiment score of 0.44 beat enVVeno Medical's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
enVVeno Medical	Neutral
GlucoTrack	Neutral

Summary

enVVeno Medical beats GlucoTrack on 7 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to Nexalin Technology?

GlucoTrack (NASDAQ:GCTK) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

GlucoTrack has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, suggesting that its share price is 300% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 5.9% of GlucoTrack shares are held by insiders. Comparatively, 16.9% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, GlucoTrack and GlucoTrack both had 3 articles in the media. GlucoTrack's average media sentiment score of 0.44 beat Nexalin Technology's score of 0.34 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nexalin Technology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GlucoTrack has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Nexalin Technology's return on equity of -278.24% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

Nexalin Technology has higher revenue and earnings than GlucoTrack. Nexalin Technology is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$9.18	N/A
Nexalin Technology	$300K	24.86	-$8.22M	-$0.48	N/A

Summary

Nexalin Technology beats GlucoTrack on 7 of the 11 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.68M	$5.88B	$7.32B	$12.82B
Dividend Yield	N/A	1.75%	2.54%	10.79%
P/E Ratio	-0.04	26.54	272.89	24.33
Price / Sales	N/A	71.19	596.33	74.53
Price / Cash	N/A	33.71	29.03	36.90
Price / Book	0.12	6.22	11.32	6.42
Net Income	-$19.39M	$149.90M	$3.47B	$348.89M
7 Day Performance	1.58%	1.18%	2.18%	0.51%
1 Month Performance	19.30%	9.23%	7.61%	4.84%
1 Year Performance	-93.72%	8.16%	25.18%	17.04%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	0.6606 of 5 stars	$0.35 flat	N/A	-93.7%	$2.68M	N/A	N/A	5	Gap Down
ICCM IceCure Medical	2.9611 of 5 stars	$2.52 -3.1%	$52.50 +1,983.3%	-90.8%	$8.91M	$3.38M	N/A	60	Gap Up
HSCS HeartSciences	2.341 of 5 stars	$2.55 +19.7%	$8.00 +213.7%	-23.3%	$8.31M	N/A	N/A	10	Gap Down High Trading Volume
INBS Intelligent Bio Solutions	1.4247 of 5 stars	$2.67 -17.1%	N/A	-83.0%	$7.70M	$3.05M	N/A	10	Earnings Report High Trading Volume
NVNO enVVeno Medical	1.4108 of 5 stars	$10.48 -5.0%	N/A	-70.6%	$7.53M	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. ICCM, HSCS, INBS, NVNO, and NXL

How does GlucoTrack compare to IceCure Medical?

Summary

How does GlucoTrack compare to HeartSciences?

Summary

How does GlucoTrack compare to Intelligent Bio Solutions?

Summary

How does GlucoTrack compare to enVVeno Medical?

Summary

How does GlucoTrack compare to Nexalin Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. ICCM, HSCS, INBS, NVNO, and NXL

How does GlucoTrack compare to IceCure Medical?

Is GCTK or ICCM more profitable?

Does the media prefer GCTK or ICCM?

Do analysts recommend GCTK or ICCM?

Do insiders and institutionals have more ownership in GCTK or ICCM?

Which has better valuation & earnings, GCTK or ICCM?

Which has more risk & volatility, GCTK or ICCM?

Summary

How does GlucoTrack compare to HeartSciences?

Do analysts recommend HSCS or GCTK?

Which has more risk and volatility, HSCS or GCTK?

Do insiders & institutionals believe in HSCS or GCTK?

Is HSCS or GCTK more profitable?

Does the media favor HSCS or GCTK?

Which has stronger valuation & earnings, HSCS or GCTK?

Summary

How does GlucoTrack compare to Intelligent Bio Solutions?

Does the media refer more to GCTK or INBS?

Do insiders & institutionals hold more shares of GCTK or INBS?

Is GCTK or INBS more profitable?

Which has preferable earnings and valuation, GCTK or INBS?

Do analysts recommend GCTK or INBS?

Which has more volatility & risk, GCTK or INBS?

Summary

How does GlucoTrack compare to enVVeno Medical?

Is NVNO or GCTK more profitable?

Which has higher valuation & earnings, NVNO or GCTK?

Which has more volatility and risk, NVNO or GCTK?

Do insiders & institutionals have more ownership in NVNO or GCTK?

Do analysts rate NVNO or GCTK?

Does the media prefer NVNO or GCTK?

Summary

How does GlucoTrack compare to Nexalin Technology?

Which has more volatility and risk, GCTK or NXL?

Do analysts prefer GCTK or NXL?

Do insiders and institutionals hold more shares of GCTK or NXL?

Does the media favor GCTK or NXL?

Is GCTK or NXL more profitable?

Which has better valuation and earnings, GCTK or NXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools